Valuation Summit Therapeutics Inc.

Stocks

Market Closed - Nasdaq 00:00:00 03/10/2026 +04			5-day change	1st Jan Change
16.76 ^USD	+0.39%		+7.34%	-4.20%

09-22	Akeso, Inc. and Summit Therapeutics Inc. Showcase HARMONi-G11 Phase III Trial Data Featuring Ivonescimab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer At ESMO 2026	CI
09-15	Summit Therapeutics Presents Updated HarmonI Data At WCLC 2026 Demonstrating Consistent Overall Survival Results With Ivonescimab Plus Chemotherapy In Western And Asian Patients	CI

Data adjusted to current consolidation scope

Fiscal Period: December	2023	2024	2025	2026	2027	2028
Market Cap ¹	1,436	10,512	10,021	10,103	-	-
Change	-	631.97%	-4.67%	0.82%	-	-
Enterprise Value (EV) ¹	1,436	10,512	9,493	9,633	9,903	9,807
Change	-	631.97%	-9.69%	1.48%	2.8%	-0.97%
P/E	-2.62x	-58.1x	-12.2x	-14.6x	-14.5x	-24.8x
PBR	-	-	20.7x	50.1x	507x	31.6x
PEG	-	0.8x	-0x	0.8x	-20.44x	0.6x
Capitalization / Revenue	-	-	-	3,446x	241x	23.6x
EV / Revenue	-	-	-	3,285x	237x	22.9x
EV / EBITDA	-	-96.9x	-11.7x	-16.8x	-18.1x	-31.3x
EV / EBIT	-	-58.8x	-11.7x	-14.4x	-13.7x	-21.7x
EV / FCF	-	-93.4x	-39.6x	-16.8x	-13.9x	-17x
FCF Yield	-	-1.07%	-2.52%	-5.96%	-7.17%	-5.89%
Dividend per Share ²	-	-	-	-	-	-
Rate of return	-	-	-	-	-	-
EPS ²	-0.7828	-0.2452	-1.066	-0.8698	-0.876	-0.51
Distribution rate	-	-	-	-	-	-
Net sales ¹	-	-	-	2.932	41.86	428.8
EBITDA ¹	-	-108.4	-810.4	-572.6	-548	-313.1
EBIT ¹	-	-178.8	-810.5	-671.1	-724.1	-451.4
Net income ¹	-486.2	-175.1	-799.5	-698.3	-741	-431.5
Net Debt ¹	-	-	-528.6	-469.9	-200.1	-296.3
Reference price ²	2.05	14.25	13.00	12.66	12.66	12.66
Nbr of stocks (in thousands)	700,843	737,448	771,150	797,750	-	-
Announcement Date	20/02/24	24/02/25	23/02/26	-	-	-

¹GBP in Million²GBP

Estimates

Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E (Y)	EV / Sales (Y)	EV / EBITDA (Y)	Dividend Yield (Y)	Capi.($)
SUMMIT THERAPEUTICS INC.	-14.56x	3285.29x	-16.82x	-.--%	13.37B
WUXI APPTEC CO., LTD.	21.73x	7.71x	15.48x	1.37%	74.16B
ARGENX SE	29.82x	8.57x	26.7x	0.04%	57.39B
LONZA GROUP AG	32.98x	5.93x	17.77x	0.98%	47.64B
REVOLUTION MEDICINES, INC.	-21.31x	230.81x	-22.97x	-.--%	44.29B
IQVIA HOLDINGS INC.	33.26x	3.23x	13.97x	-.--%	42.5B
BEONE MEDICINES AG	46.77x	5.41x	29.66x	-.--%	40.71B
CELLTRION, INC.	27.63x	7.93x	20.48x	0.41%	30.97B
WUXI BIOLOGICS (CAYMAN) INC.	32.99x	7.05x	18.3x	-.--%	28.53B
BIONTECH SE	-15.1x	5.68x	-7.14x	-.--%	24.34B
Average	17.42x	356.76x	9.54x	0.28%	40.39B
Weighted average by Cap.	21.05x	139.70x	12.55x	0.4%